1. The glucocorticoid receptor inhibits NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) through several parallel actions. Which mechanism specifically describes direct protein-protein tethering rather than cytoplasmic sequestration or chromatin remodeling?
A) Induction of IkappaB-alpha through a glucocorticoid response element, increasing the cytoplasmic pool that holds NF-kappaB inactive
B) Recruitment of histone deacetylase 2 (HDAC2) to inflammatory gene promoters to reverse histone acetylation
C) Direct binding of the activated glucocorticoid receptor monomer to the p65 subunit of NF-kappaB, blocking its interaction with coactivator complexes
D) Accelerated proteasomal degradation of the p65 subunit
E) Phosphorylation of NF-kappaB to promote its nuclear export
ANSWER: C
Rationale:
Direct tethering refers to the activated glucocorticoid receptor monomer physically binding the p65 subunit of NF-kappaB, which prevents p65 from engaging its coactivator complexes and blocks transcription of NF-kappaB target genes. This protein-protein interaction is distinct from the other parallel mechanisms, making Option C correct.
Option A: Option A is incorrect because IkappaB-alpha induction works by sequestering NF-kappaB in the cytoplasm, an indirect mechanism rather than direct tethering at the gene.
Option B: Option B is incorrect because HDAC2 recruitment is a chromatin-remodeling action that closes the promoter, not a direct binding interaction with p65.
Option D: Option D is incorrect because glucocorticoids do not act primarily by driving proteasomal degradation of p65.
Option E: Option E is incorrect because glucocorticoid control of NF-kappaB does not depend on phosphorylating it to promote nuclear export; the established mechanisms are tethering, IkappaB-alpha induction, and HDAC2 recruitment.
2. Glucocorticoids reduce eicosanoid output through both an upstream substrate-limiting action and a transcriptional action. Which option correctly identifies the upstream substrate-limiting step?
A) Annexin-A1 induction inhibits cytosolic phospholipase A2, reducing release of arachidonic acid, the shared substrate for all eicosanoid pathways
B) Transcriptional repression of the COX-2 (cyclooxygenase-2) gene through NF-kappaB and AP-1 inhibition
C) Direct catalytic inhibition of cyclooxygenase, identical to the NSAID mechanism
D) Inhibition of thromboxane synthase downstream of cyclooxygenase
E) Blockade of leukotriene receptors on target cells
ANSWER: A
Rationale:
The upstream substrate-limiting step is induction of annexin-A1, which inhibits cytosolic phospholipase A2 (PLA2) and thereby reduces the release of arachidonic acid, the common substrate feeding both the cyclooxygenase and lipoxygenase pathways. Limiting substrate at the top of the cascade is what gives glucocorticoids their broad effect, making Option A correct.
Option B: Option B is incorrect because COX-2 transcriptional repression is the transcriptional action, not the upstream substrate-limiting step the question asks for.
Option C: Option C is incorrect because direct catalytic inhibition of cyclooxygenase describes NSAIDs, and glucocorticoids do not act this way.
Option D: Option D is incorrect because thromboxane synthase inhibition is a distal step affecting only one product, not an upstream substrate-limiting action.
Option E: Option E is incorrect because blocking leukotriene receptors acts on the end organ rather than limiting substrate availability upstream.
3. Glucocorticoids suppress one isoform of nitric oxide synthase as part of their anti-inflammatory action. Which statement correctly identifies the targeted isoform and the consequence of its suppression?
A) Constitutive endothelial NOS (eNOS) is suppressed, abolishing normal vascular tone
B) Constitutive neuronal NOS (nNOS) is suppressed, blocking neurotransmission
C) All nitric oxide synthase isoforms are suppressed equally regardless of inducibility
D) Inducible NOS (iNOS) is suppressed through NF-kappaB inhibition, reducing high-output nitric oxide that drives vasodilation, vascular permeability, and oxidative tissue damage
E) Nitric oxide synthase activity is increased to enhance perfusion at inflamed sites
ANSWER: D
Rationale:
Glucocorticoids suppress inducible nitric oxide synthase (iNOS), whose expression is driven by pro-inflammatory cytokines through NF-kappaB. Reducing the high-output nitric oxide produced by iNOS at inflamed sites decreases vasodilation, vascular permeability, and peroxynitrite-mediated oxidative damage, contributing to the rapid fall in local swelling. This makes Option D correct.
Option A: Option A is incorrect because the constitutive endothelial isoform that maintains normal vascular tone is not the inflammatory target, and abolishing it is not the mechanism.
Option B: Option B is incorrect because the constitutive neuronal isoform involved in neurotransmission is not the inducible inflammatory enzyme suppressed here.
Option C: Option C is incorrect because the suppression is selective for the inducible isoform driven by inflammatory signaling, not uniform across all isoforms.
Option E: Option E is incorrect because glucocorticoids reduce, rather than increase, nitric oxide synthase activity at inflamed sites.
4. Among the anti-inflammatory actions of glucocorticoids, which one operates at the post-transcriptional level rather than by repressing gene transcription?
A) GR-alpha tethering to p65 to block NF-kappaB-driven transcription
B) Induction of MKP-1 (MAP kinase phosphatase-1), which inactivates p38 MAPK and JNK and accelerates decay of cytokine messenger RNA
C) AP-1 (activator protein 1) inhibition reducing matrix metalloproteinase gene expression
D) HDAC2 recruitment closing chromatin at inflammatory promoters
E) IkappaB-alpha induction sequestering NF-kappaB in the cytoplasm
ANSWER: B
Rationale:
MKP-1 (MAP kinase phosphatase-1) induction is the post-transcriptional arm. By dephosphorylating and inactivating p38 MAPK and JNK, MKP-1 removes the stabilization those kinases provide to cytokine messenger RNA, accelerating mRNA decay and lowering cytokine protein output independently of transcription. This makes Option B correct.
Option A: Option A is incorrect because GR-alpha tethering to p65 blocks transcription, a transcriptional action.
Option C: Option C is incorrect because AP-1 inhibition acts at the level of gene transcription.
Option D: Option D is incorrect because HDAC2 recruitment is a chromatin-level transcriptional mechanism.
Option E: Option E is incorrect because IkappaB-alpha induction acts upstream of transcription by keeping NF-kappaB out of the nucleus, not at the post-transcriptional level.
5. Which statement most precisely describes the two concurrent mechanisms producing glucocorticoid-induced neutrophilia?
A) Increased granulopoiesis combined with prolonged neutrophil survival
B) Enhanced margination to endothelium combined with reduced marrow release
C) Increased neutrophil production combined with improved antimicrobial function
D) Sequestration of neutrophils in the spleen combined with reduced apoptosis
E) Reduced margination from suppression of L-selectin and the beta-2 integrin Mac-1, combined with accelerated release of mature neutrophils from marrow storage pools
ANSWER: E
Rationale:
Glucocorticoid neutrophilia arises from two redistribution phenomena occurring together: suppression of the adhesion molecules L-selectin and the beta-2 integrin Mac-1 reduces neutrophil margination to the vascular endothelium, and mature neutrophils are released more rapidly from marrow storage pools. Neither involves increased production or enhanced function. This makes Option E correct.
Option A: Option A is incorrect because the effect is too rapid to reflect increased granulopoiesis and does not depend on prolonged survival.
Option B: Option B is incorrect because margination is reduced, not enhanced, and marrow release is increased, not reduced, so it reverses both mechanisms.
Option C: Option C is incorrect because neutrophil production is not increased and antimicrobial function is not improved.
Option D: Option D is incorrect because the mechanism is demargination and marrow release, not splenic sequestration with reduced apoptosis.
6. In humans at pharmacological doses, the predominant mechanism of glucocorticoid-induced T lymphopenia is best described as which of the following?
A) Redistribution of T lymphocytes from blood to lymphoid tissues through altered homing receptor expression, reversible within about 24 hours of a single dose
B) Predominant apoptosis of mature peripheral T cells accounting for the entire fall in count
C) Complement-mediated lysis of circulating T cells
D) Permanent depletion of the peripheral T cell pool
E) Failure of thymic output causing a gradual decline over weeks
ANSWER: A
Rationale:
In most human clinical settings the dominant mechanism is redistribution: glucocorticoid receptor-mediated changes in homing receptor expression and cytokine signals shift T lymphocytes from the circulation into lymphoid tissues such as spleen, lymph nodes, and bone marrow, and the change reverses within roughly 24 hours of a single dose. This makes Option A correct.
Option B: Option B is incorrect because, although high concentrations can induce apoptosis in immature thymocytes and activated T cells, apoptosis of mature peripheral T cells is less prominent in humans than in rodent models and does not account for the entire rapid fall.
Option C: Option C is incorrect because the cells are sequestered rather than lysed, consistent with rapid recovery.
Option D: Option D is incorrect because the lymphopenia is reversible, not a permanent depletion.
Option E: Option E is incorrect because the change occurs within hours and recovers quickly, which is inconsistent with a gradual decline from failed thymic output.
7. Glucocorticoids suppress the classically activated (M1) macrophage phenotype. Which set of changes best characterizes this effect and its clinical consequence?
A) Increased respiratory burst and enhanced intracellular killing, raising infection risk paradoxically
B) Upregulated MHC (major histocompatibility complex) class II with increased antigen presentation
C) Reduced respiratory burst, impaired phagocytosis, decreased MHC class II expression, and lower IL-12 (interleukin-12) output, contributing to opportunistic infection risk
D) Selective increase in IL-1beta and TNF-alpha production
E) Enhanced migration of macrophages to inflamed tissue
ANSWER: C
Rationale:
Glucocorticoids suppress the M1 macrophage phenotype driven by interferon-gamma and lipopolysaccharide: they reduce the respiratory burst, impair phagocytosis, decrease cell-surface MHC class II expression, and lower production of pro-inflammatory cytokines including IL-12. Because these functions are central to control of intracellular pathogens, their suppression contributes to opportunistic infection risk. This makes Option C correct.
Option A: Option A is incorrect because the respiratory burst and intracellular killing are reduced, not increased.
Option B: Option B is incorrect because MHC class II is downregulated, reducing antigen presentation rather than increasing it.
Option D: Option D is incorrect because IL-1beta and TNF-alpha production is suppressed, not selectively increased.
Option E: Option E is incorrect because macrophage and dendritic cell migration is impaired, not enhanced.
8. Which glucocorticoid effect on granulocytes has historically been used as one of the fastest and most sensitive pharmacodynamic indicators of glucocorticoid receptor engagement?
A) Suppression of stem cell factor (SCF) reducing tissue mast cell numbers over weeks
B) Rapid eosinophil apoptosis producing a prompt fall in the blood eosinophil count after a single dose
C) Neutrophil demargination raising the circulating neutrophil count
Glucocorticoids drive eosinophil apoptosis, and the resulting fall in the blood eosinophil count after a single systemic dose is one of the fastest and most sensitive indicators of glucocorticoid bioactivity; it was historically used to demonstrate receptor engagement in pharmacodynamic studies. This makes Option B correct.
Option A: Option A is incorrect because suppression of stem cell factor reduces mast cell numbers gradually over prolonged use and is not a rapid, sensitive marker of receptor engagement.
Option C: Option C is incorrect because neutrophil demargination reflects redistribution and is not the classic rapid pharmacodynamic readout of receptor engagement.
Option D: Option D is incorrect because glucocorticoids do not characteristically cause basophil degranulation.
Option E: Option E is incorrect because reduced mast cell mediator release contributes to the therapeutic effect in allergic airways disease but is not the quick quantitative blood marker used to confirm receptor engagement.
9. When a glucocorticoid is indicated for a hospitalized patient with COVID-19-associated acute respiratory distress syndrome (ARDS) requiring oxygen, which pharmacological properties make dexamethasone a logical choice?
A) Strong mineralocorticoid activity that supports intravascular volume in respiratory failure
B) A very short duration of action requiring frequent redosing to maintain effect
C) Low potency necessitating large oral volumes
D) A long biologic duration permitting once-daily dosing, absence of mineralocorticoid activity that avoids sodium and fluid retention, and high potency allowing a small effective dose
E) Selective inhaled delivery confining the drug to the airway
ANSWER: D
Rationale:
Dexamethasone suits this setting because its long biologic duration of action allows once-daily dosing, its negligible mineralocorticoid activity avoids sodium and fluid retention in patients at risk of volume overload, and its high potency achieves adequate immunosuppression at a small dose. This makes Option D correct.
Option A: Option A is incorrect because dexamethasone has negligible, not strong, mineralocorticoid activity, and avoiding fluid retention is one reason it is preferred.
Option B: Option B is incorrect because dexamethasone is long-acting, which is precisely why once-daily dosing is feasible.
Option C: Option C is incorrect because dexamethasone is high-potency, requiring only a small dose rather than large volumes.
Option E: Option E is incorrect because dexamethasone here is given systemically for the host inflammatory response, not as an inhaled airway-confined agent.
10. For a patient in septic shock, at what point does low-dose hydrocortisone become an appropriate adjunct according to current synthesis of the major trials?
A) At the first recognition of sepsis, before fluid resuscitation
B) In any hospitalized patient with infection regardless of hemodynamics
C) Only after a short ACTH (adrenocorticotropic hormone) stimulation test confirms a responder
D) As a replacement for vasopressors once shock is established
E) When shock remains refractory after adequate fluid resuscitation and requires high, escalating vasopressor support
ANSWER: E
Rationale:
The synthesis of the major septic shock trials supports low-dose hydrocortisone (about 200 mg per day) when shock persists despite adequate fluid resuscitation and demands high, escalating vasopressor doses; fludrocortisone may be added in this refractory setting. This makes Option E correct.
Option A: Option A is incorrect because hydrocortisone is not started before resuscitation or at first recognition of sepsis; it is reserved for refractory shock.
Option B: Option B is incorrect because it is not indicated for all infected patients irrespective of hemodynamics.
Option C: Option C is incorrect because the short ACTH stimulation test was found not to identify a benefiting subgroup and is not used to select patients.
Option D: Option D is incorrect because hydrocortisone is an adjunct, not a substitute for vasopressors.
11. In bacterial meningitis, adjunctive dexamethasone reduces severe neurological sequelae. What timing of administration relative to antibiotics is required for this benefit?
A) Given with or immediately before the first antibiotic dose
B) Given only after 48 hours of antibiotic therapy
C) Given several days after antibiotics once cultures return
D) Given only if the patient fails to improve on antibiotics alone
E) Given after the inflammatory response has fully resolved
ANSWER: A
Rationale:
Adjunctive dexamethasone must be given with or immediately before the first antibiotic dose. Antibiotic-induced bacterial lysis releases components that trigger an intense subarachnoid inflammatory response, and suppressing that response at the moment of lysis is what reduces severe sequelae such as sensorineural hearing loss. This makes Option A correct.
Option B: Option B is incorrect because waiting 48 hours misses the inflammatory surge that accompanies initial bacterial killing.
Option C: Option C is incorrect because delaying until cultures return forfeits the timing window.
Option D: Option D is incorrect because dexamethasone is not reserved as rescue after antibiotic failure; the benefit depends on early co-administration.
Option E: Option E is incorrect because giving it after inflammation has resolved provides no protective effect against the early lysis-driven injury.
12. In a transplant recipient, which CYP3A4 (cytochrome P450 3A4)-mediated interaction correctly pairs the perturbation with its clinical consequence?
A) Rifampin inhibits CYP3A4, raising methylprednisolone levels and causing toxicity
B) Cyclosporine induces CYP3A4, lowering glucocorticoid levels and risking rejection
C) Cyclosporine inhibits CYP3A4, which can increase methylprednisolone exposure, while CYP3A4 induction by rifampin or anticonvulsants can lower glucocorticoid levels and precipitate rejection
D) Anticonvulsants inhibit CYP3A4, increasing glucocorticoid exposure without clinical effect
E) CYP3A4 has no role in glucocorticoid metabolism in transplant patients
ANSWER: C
Rationale:
Cyclosporine inhibits CYP3A4 and can moderately increase methylprednisolone exposure, whereas CYP3A4 inducers such as rifampin and certain anticonvulsants reduce glucocorticoid levels and can precipitate rejection by dropping immunosuppression below the therapeutic threshold. This correct pairing of perturbation and consequence makes Option C correct.
Option A: Option A is incorrect because rifampin induces rather than inhibits CYP3A4, so it lowers, not raises, methylprednisolone levels.
Option B: Option B is incorrect because cyclosporine inhibits rather than induces CYP3A4.
Option D: Option D is incorrect because anticonvulsants are typically inducers, lowering glucocorticoid exposure, and the change is clinically meaningful.
Option E: Option E is incorrect because CYP3A4 is directly relevant to glucocorticoid metabolism and to these interactions.
13. Which statement correctly distinguishes the systemic handling of fluticasone propionate and budesonide as inhaled corticosteroids?
A) Both agents have high oral bioavailability and minimal first-pass metabolism
B) Fluticasone propionate has very low gastrointestinal bioavailability and the lowest systemic exposure among common agents, while budesonide undergoes approximately 85 to 90 percent first-pass hepatic metabolism of the swallowed and absorbed fractions
C) Budesonide has higher systemic bioavailability than fluticasone because it escapes first-pass metabolism entirely
D) Fluticasone propionate is an inactive prodrug requiring airway esterase activation
Fluticasone propionate has very low gastrointestinal bioavailability (about 1 percent) and the lowest systemic exposure among commonly used inhaled corticosteroids, while budesonide undergoes roughly 85 to 90 percent first-pass hepatic metabolism of both swallowed and absorbed fractions. This correct contrast makes Option B correct.
Option A: Option A is incorrect because both agents are characterized by low oral bioavailability and substantial first-pass metabolism, not the opposite.
Option C: Option C is incorrect because budesonide does undergo extensive first-pass metabolism rather than escaping it.
Option D: Option D is incorrect because the esterase-activated airway prodrug is ciclesonide, not fluticasone propionate.
Option E: Option E is incorrect because first-pass metabolism is central to the favorable systemic profile of these agents.
14. Which inhaled corticosteroid is an inactive prodrug that is converted to its active form by esterases within the airway epithelium, enhancing its topical selectivity?
A) Fluticasone propionate
B) Budesonide
C) Beclomethasone dipropionate administered systemically
D) Ciclesonide
E) Hydrocortisone
ANSWER: D
Rationale:
Ciclesonide is administered as an inactive prodrug and is activated by esterases in the airway epithelium, so meaningful drug activity is generated preferentially at the site of action, enhancing topical selectivity and limiting systemic effect. This makes Option D correct.
Option A: Option A is incorrect because fluticasone propionate is administered as an active agent and is not an esterase-activated prodrug.
Option B: Option B is incorrect because budesonide is an active agent characterized by extensive first-pass metabolism rather than airway prodrug activation.
Option C: Option C is incorrect because beclomethasone dipropionate is an inhaled agent for airway disease and is not the esterase-activated airway prodrug described, and systemic administration is not its inhaled use.
Option E: Option E is incorrect because hydrocortisone is a systemic and topical glucocorticoid, not an inhaled airway prodrug.
15. For topical glucocorticoids, how does vehicle selection relate to drug penetration and potency class?
A) Ointments provide the highest skin penetration through an occlusive effect, creams are intermediate and better tolerated on moist or intertriginous skin, and lotions suit the scalp; vehicle modifies penetration independently of the potency class
B) Lotions penetrate best because of their high water content, exceeding ointments
C) Vehicle has no effect on absorption; only the potency class matters
D) Creams always penetrate more than ointments because they spread more easily
E) Potency class and vehicle are the same property expressed in different units
ANSWER: A
Rationale:
Vehicle and potency class are separate pharmacological axes. Ointments give the highest penetration because their occlusive effect enhances absorption, creams are intermediate and better tolerated on moist or intertriginous skin, and lotions are preferred for the scalp; the vehicle modifies penetration independently of where the agent falls in the seven potency classes. This makes Option A correct.
Option B: Option B is incorrect because lotions do not penetrate better than ointments; ointments are the most penetrating vehicle.
Option C: Option C is incorrect because vehicle does meaningfully affect absorption and is as pharmacologically important as potency.
Option D: Option D is incorrect because creams generally penetrate less than occlusive ointments, not more.
Option E: Option E is incorrect because potency class (a measure of glucocorticoid potency) and vehicle (a determinant of penetration) are distinct properties, not the same property in different units.
16. Which option correctly distinguishes the hydrocortisone stress-dose protocols for moderate versus major surgery in a patient with presumed HPA (hypothalamic-pituitary-adrenal) axis suppression?
A) Moderate and major surgery use identical regimens of 100 mg at induction with no further dosing
B) Moderate surgery requires higher dosing than major surgery because of shorter operative time
C) Neither category requires supplementation beyond the usual oral dose
D) Major surgery uses 50 mg at induction while moderate surgery uses 100 mg
E) Moderate surgery: hydrocortisone 50 mg intravenously at induction, then 25 mg every 8 hours for 24 hours; major surgery: 100 mg at induction, then 50 mg every 8 hours for the first 24 hours with taper over 48 to 72 hours
ANSWER: E
Rationale:
The protocols are stratified by surgical magnitude. Moderate procedures call for hydrocortisone 50 mg intravenously at induction followed by 25 mg every 8 hours for 24 hours, then return to the usual dose; major procedures call for 100 mg at induction followed by 50 mg every 8 hours for the first 24 hours, with a gradual taper over 48 to 72 hours back to the chronic dose. This correct discrimination makes Option E correct.
Option A: Option A is incorrect because the two categories do not use identical single-dose regimens; both involve repeated dosing scaled to stress.
Option B: Option B is incorrect because major surgery requires higher, not lower, dosing than moderate surgery.
Option C: Option C is incorrect because patients with presumed suppression do require supplementation for moderate and major procedures.
Option D: Option D is incorrect because it reverses the induction doses; major surgery uses the higher 100 mg induction dose and moderate surgery the lower 50 mg dose.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.